Genmab — September 2019
-
Fandt lige det her: FDA informs the applicant of a Priority Review designation within 60 days of the receipt of the original BLA. - Og det var i tirsdags. Har skrevet og spurgt Andrew Carlsen om de overhovedet har søgt. https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/priority-review
-
New DARZALEX
(daratumumab) Data from GRIFFIN Study Show High Response Rate and Depth of Response in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant-Eligible https://www.prnewswire.com/news-releases/new-darzalex-daratumumab-data-from-griffin-study-show-high-response-rate-and-depth-of-response-in-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible-300918272.html -
-
-
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind